Adjuvant therapy of gastrointestinal stromal tumors (GIST)

Current Treatment Options in Oncology

Volumn 13, Issue 3, 2012, Pages 277-284

  Casali, Paolo G ^a   Fumagalli, Elena ^a   Gronchi, Alessandro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adjuvant therapy; Gastrointestinal stromal tumors; Imatinib

Indexed keywords

ASPARTIC ACID; IMATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; VALINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CYTOREDUCTIVE SURGERY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; GASTROINTESTINAL STROMAL TUMOR; GENOTYPE; HIGH RISK POPULATION; HUMAN; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; TUMOR LOCALIZATION; TUMOR RESISTANCE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; GENOTYPE; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TREATMENT OUTCOME;

EID: 84865686981     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-012-0198-0     Document Type: Article

References (36)

1. CD Blanke, et al. 2008 Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 4 620 625 18235121 10.1200/JCO.2007.13.4403 1:CAS:528: DC%2BD1cXis1alsL0%3D
2. J Verweij, et al. 2004 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 9440 1127 1134 15451219 10.1016/S0140-6736(04)17098-0 1:CAS:528:DC%2BD2cXnvVOiu7o%3D
3. CD Blanke, et al. 2008 Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 J Clin Oncol 26 4 626 632 18235122 10.1200/JCO.2007.13.4452 1:CAS:528:DC%2BD1cXis1alsLs%3D
4. RP Dematteo, et al. 2008 Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) Cancer 112 3 608 615 18076015 10.1002/cncr.23199
5. M Von Mehren, et al. 2011 Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT∈+∈gastrointestinal stromal tumors (GIST) J Clin Oncol 29 Suppl 10016
6. M Van Glabbeke, et al. 2005 Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study J Clin Oncol 23 24 5795 5804 16110036 10.1200/JCO.2005.11.601
7. A Blesius, et al. 2011 Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French Sarcoma Group randomized phase III trial J Clin Oncol 29 Suppl 10048
8. RP DeMatteo, et al. 2009 Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet 373 9669 1097 1104 19303137 10.1016/S0140- 6736(09)60500-6 1:CAS:528:DC%2BD1MXjslOltro%3D
9. H Joensuu, et al. 2012 One vs. three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial JAMA 307 12 1265 1272 22453568 10.1001/jama.2012.347 1:CAS:528:DC%2BC38XltVCks78%3D
10. A Le Cesne, et al. 2010 Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial The Lancet Oncology 11 10 942 949 20864406 10.1016/S1470-2045(10)70222-9
11. J Domont, et al. 2011 Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomized phase III trial J Clin Oncol 29 Suppl 10054
12. GD Demetri, et al. 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 9544 1329 1338 17046465 10.1016/S0140-6736(06)69446-4 1:CAS:528:DC%2BD28XhtVOrtL%2FL
13. Reichardt P, et al. Response to imatinib rechallenge of GIST that recurs following completion of adjuvant imatinib treatment-the first analysis in the SSGXVIII/AIO trial patient population. ECCO-ESMO 2011 (Abstr 31LBA).
14. M Miettinen, et al. 2006 Gastrointestinal stromal tumors: pathology and prognosis at different sites Semin Diagn Pathol 23 2 70 83 17193820 10.1053/j.semdp.2006.09.001
15. H Joensuu, et al. 2008 Risk stratification of patients diagnosed with gastrointestinal stromal tumor Hum Pathol 39 10 1411 1419 18774375 10.1016/j.humpath.2008.06.025
16. JS Gold, et al. 2009 Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis The Lancet Oncology 10 11 1045 1052 19793678 10.1016/S1470-2045(09)70242-6
17. S Rossi, et al. 2011 Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables Am J Surg Pathol 35 11 1646 1656 21997685 10.1097/PAS.0b013e31822d63a7
18. P Hohenberger, et al. 2010 Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour Br J Surg 97 12 1854 1859 20730857 10.1002/bjs.7222 1:STN:280:DC%2BC3cbltF2nsA%3D%3D
19. P Rutkowski, et al. 2011 Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour: the impact of tumour rupture on patient outcomes Eur J Surg Oncol 37 10 890 896 21737227 10.1016/j.ejso.2011.06.005 1:STN:280:DC%2BC3Mfkt1aqsg%3D%3D
20. MC Heinrich, et al. 2003 Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 23 4342 4349 14645423 10.1200/JCO.2003.04.190 1:CAS:528:DC%2BD2cXpsVWqu7Y%3D
21. J Martin-Broto, et al. 2010 Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study Ann Oncol 21 7 1552 1557 20231303 10.1093/annonc/mdq047 1:STN:280:DC%2BC3crmsVSqsQ%3D%3D
22. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) 2010 Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients J Clin Oncol 28 7 1247 1253 10.1200/JCO.2009.24.2099
23. CL Corless, et al. 2005 PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib J Clin Oncol 23 23 5357 5364 15928335 10.1200/JCO.2005.14.068 1:CAS:528:DC%2BD2MXpslOrtLY%3D
24. J Lasota, et al. 2008 Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours Histopathology 53 3 245 266 18312355 10.1111/j.1365-2559.2008.02977.x 1:STN:280:DC%2BD1cnmslyjsQ%3D%3D
25. Emile JF, et al. Frequencies of KIT and PDGFRAmutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2011; Sep 28 [Epub ahead of print]. This population-based series shows that the frequency of PDGFRA mutations (including the insensitive mutation PDGFRA D842V) in the localized setting is higher than observed in advanced series (given its better prognosis, although in the face of its insensitivity to targeted therapy).
26. JA Carney, et al. 2002 Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad Am J Med Genet 108 2 132 139 11857563 10.1002/ajmg.10235
27. M Miettinen, et al. 2006 Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases Am J Surg Pathol 30 1 90 96 16330947 10.1097/01.pas.0000176433.81079.bd
28. C Mussi, et al. 2008 Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1 Clin Cancer Res 14 14 4550 4555 18628470 10.1158/1078-0432.CCR-08-0086 1:CAS:528:DC%2BD1cXosFGitb4%3D
29. M Miettinen, et al. 2005 Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature Am J Surg Pathol 29 10 1373 1381 16160481 10.1097/01.pas.0000172190. 79552.8b
30. P Agaram, et al. 2008 Molecular characterization of pediatric gastrointestinal stromal tumors Clin Cancer Res 14 10 3204 3215 18483389 10.1158/1078-0432.CCR-07-1984 1:CAS:528:DC%2BD1cXmtVCmu78%3D
31. M Fiore, et al. 2009 Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumours (GIST) Eur J Sur Oncol. 35 7 739 745 10.1016/j.ejso.2008.11.005 1:STN:280:DC%2BD1MzmtlersQ%3D%3D
32. Wang D, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of radiation therapy oncology group 0132. Ann Surg Oncol. 2011; Mar 7 [Epub ahead of print].
33. Gronchi A, et al. The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. Ann Surg Oncol. 2011; [Epub ahead of print] doi: 10.1245/s10434-011-2191-4.
34. H Choi, et al. 2008 Response evaluation of gastrointestinal stromal tumors Oncologist 13 2 4 7 18434631 10.1634/theoncologist.13-S2-4
35. AD Van den Abbeele, et al. 2008 The lessons of GIST-PET and PET/CT: a new paradigm for imaging Oncologist 13 2 8 13 18434632 10.1634/theoncologist.13-S2- 8
36. F Haller, et al. 2007 Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations Ann Surg Oncol 14 2 526 532 17139461 10.1245/s10434-006-9228-0